Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA. et al, (2017), Lancet Haematol, 4, e225 - e236
Pre-metastatic niches: organ-specific homes for metastases.
Peinado H. et al, (2017), Nature reviews. Cancer, 17, 302 - 317
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A. et al, (2017), Blood, 129, 2224 - 2232
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
Lahr RM. et al, (2017), eLife, 6
A practical application of time to event analysis in the presence of non-proportional hazards
Mohammed SB. et al, (2017)
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
Eyre TA. et al, (2017), British journal of haematology
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104, 408 - 417
The RNA-binding protein LARP1 is a cancer therapeutic target
Ghazaly EA. et al, (2017), CANCER RESEARCH, 77
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Hall PS. et al, (2017), British journal of cancer, 116, 472 - 478
Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
Long GV. et al, (2017), EUROPEAN JOURNAL OF CANCER, 72, S128 - S129
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A. et al, (2017), PLoS Med, 14, e1002230 - e1002230
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 527 - 528
Guideline for the investigation and management of eosinophilia
Butt NM. et al, (2017), British Journal of Haematology, 176, 553 - 572
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Middleton MR. et al, (2017), British Journal of Cancer
Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment
Beusterien K. et al, (2017), Journal of Cancer Therapy, 8, 37-50
FIRST-IN-CLASS, ORAL MUTANT IDH2 INHIBITOR REVERSES DIFFERENTIATION BLOCK IN ACUTE MYELOID LEUKAEMIA TO PRODUCE CLINICALLY MEANINGFUL RESPONSES
Vyas P., (2017), EXPERIMENTAL HEMATOLOGY, 53, S38 - S38
Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells
Stavraka C. et al, (2017), CANCER RESEARCH, 77
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
Ait-Tahar K. et al, (2017), Adv Hematol, 2017